ELVNEnliven Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 14742
Ticker: ELVN
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2023-02-24
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: ELVN

Detail

Enriched 2026-08-14 20:47

Market cap: $4,243,842,477.12
Shares outstanding (class): 73,270,761
Shares outstanding (weighted): 73,270,761
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 67
Location: BURLINGAME, CA
Homepage: https://www.enliventherapeutics.com
Description: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Market cap and share counts drift.

Funds holding this security

79 funds · 80 positions · $199.73M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$63.36M	0.00%	1,616,362 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$37.88M	0.05%	966,241 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$19.50M	0.02%	497,384 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$12.64M	0.16%	322,556 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$12.53M	0.10%	319,687 NS	FIGI
VIP Health Care Portfolio Variable Insurance Products Fund IV	—	$8.55M	0.85%	218,000 NS	FIGI
State Street(R) SPDR(R) S&P(R) Pharmaceuticals … SPDR SERIES TRUST	XPH	$7.54M	2.45%	192,297 NS	FIGI
iShares U.S. Pharmaceuticals ETF iShares Trust	IHE	$4.88M	0.49%	124,406 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$3.89M	0.32%	99,196 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$2.78M	0.00%	70,971 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$2.39M	0.05%	60,923 NS	FIGI
BlackRock Health Sciences Term Trust —	—	$2.15M	0.21%	54,885 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$2.11M	0.02%	53,863 NS	FIGI
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$1.58M	0.05%	40,389 NS	FIGI
NICHOLAS PARTNERS SMALL CAP GROWTH FUND ADVISORS' INNER CIRCLE III	—	$1.41M	0.94%	35,883 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERELVN
FIGI_COMPOSITEBBG00CP3BDD4
FIGI_SHARE_CLASSBBG00CP3BDF2
CIK0001672619
ISINUS29337E1029
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: The company is a biopharmaceutical firm focused on precision oncology, classified under SIC 2834 for pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.